Molecular mechanisms leading to ceftolozane/tazobactam resistance in clinical isolates of Pseudomonas aeruginosa from five Latin American countries

Autores
Mojica, María F.; De La Cadena, Elsa; Ríos, Rafael; García Betancur, Juan Carlos; Díaz, Lorena; Reyes, Jinnethe; Hernández Gómez, Cristhian; Radice, Marcela Alejandra; Gales, Ana C.; Castañeda Méndez, Paulo; Munita, José M.; Pallares, Christian José; Martínez, José R. W.; Villegas, María Virginia
Año de publicación
2022
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Objectives: Identify molecular mechanisms responsible for the in vitro non-susceptibility to ceftolozane/tazobactam (TOL) in a group of 158 clinical isolates of Pseudomonas aeruginosa from five Latin American countries collected before the introduction of TOL into the clinical practice. Methods: Clinical isolates of P. aeruginosa (n = 504) were collected between January 2016 and October 2017 from 20 hospitals located in Argentina, Brazil, Chile, Colombia, and Mexico. Minimum inhibitory concentrations (MICs) to TOL were determined by standard broth microdilution and interpreted according to CLSI breakpoints. Initially, production of carbapenemases in TOL non-susceptible isolates was assessed by Rapidec® followed by qPCR to detect blaKPC, blaNDM-1, blaVIM, and blaIMP. Illumina® WGS was performed for isolates in which non-susceptibility to TOL was not mediated by carbapenemases. Results: A total of 158 (31.3%) isolates were non-susceptible to TOL. In 74 (46.8%) of these isolates, non-susceptibility to TOL was explained by the production of at least one carbapenemase. WGS revealed that some isolates carried ESBLs, mutated blaPDC and ampD, associated with decreased susceptibility to TOL. Conclusion: Substitutions found in PDC and carbapenemase production were the most common presumed mechanisms of resistance to TOL detected in this study. This study shows that epidemiological surveillance is warranted to monitor the emergence of novel mechanisms of resistance to TOL that might compromise its clinical utility.
Fil: Mojica, María F.. Case Western Reserve University; Estados Unidos
Fil: De La Cadena, Elsa. Universidad El Bosque;
Fil: Ríos, Rafael. Universidad El Bosque;
Fil: García Betancur, Juan Carlos. Universidad El Bosque;
Fil: Díaz, Lorena. Universidad El Bosque;
Fil: Reyes, Jinnethe. Universidad El Bosque;
Fil: Hernández Gómez, Cristhian. Universidad El Bosque;
Fil: Radice, Marcela Alejandra. Universidad de Buenos Aires; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Gales, Ana C.. Universidade Federal de Sao Paulo; Brasil
Fil: Castañeda Méndez, Paulo. Fundacion Clinica Medica Sur; México
Fil: Munita, José M.. Universidad del Desarrollo; Chile
Fil: Pallares, Christian José. Universidad El Bosque;
Fil: Martínez, José R. W.. Universidad del Desarrollo; Chile
Fil: Villegas, María Virginia. Universidad El Bosque;
Materia
ANTIBIOTIC RESISTANCE
CEFTOLOZANE/TAZOBACTAM
LATIN AMERICA
MOLECULAR MECHANISMS
PSEUDOMONAS AERUGINOSA
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/217847
Acceder
id CONICETDig_9e7b54e9b955a1fea6bff90478ef5725
oai_identifier_str oai:ri.conicet.gov.ar:11336/217847
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Molecular mechanisms leading to ceftolozane/tazobactam resistance in clinical isolates of Pseudomonas aeruginosa from five Latin American countriesMojica, María F.De La Cadena, ElsaRíos, RafaelGarcía Betancur, Juan CarlosDíaz, LorenaReyes, JinnetheHernández Gómez, CristhianRadice, Marcela AlejandraGales, Ana C.Castañeda Méndez, PauloMunita, José M.Pallares, Christian JoséMartínez, José R. W.Villegas, María VirginiaANTIBIOTIC RESISTANCECEFTOLOZANE/TAZOBACTAMLATIN AMERICAMOLECULAR MECHANISMSPSEUDOMONAS AERUGINOSAhttps://purl.org/becyt/ford/3.3https://purl.org/becyt/ford/3Objectives: Identify molecular mechanisms responsible for the in vitro non-susceptibility to ceftolozane/tazobactam (TOL) in a group of 158 clinical isolates of Pseudomonas aeruginosa from five Latin American countries collected before the introduction of TOL into the clinical practice. Methods: Clinical isolates of P. aeruginosa (n = 504) were collected between January 2016 and October 2017 from 20 hospitals located in Argentina, Brazil, Chile, Colombia, and Mexico. Minimum inhibitory concentrations (MICs) to TOL were determined by standard broth microdilution and interpreted according to CLSI breakpoints. Initially, production of carbapenemases in TOL non-susceptible isolates was assessed by Rapidec® followed by qPCR to detect blaKPC, blaNDM-1, blaVIM, and blaIMP. Illumina® WGS was performed for isolates in which non-susceptibility to TOL was not mediated by carbapenemases. Results: A total of 158 (31.3%) isolates were non-susceptible to TOL. In 74 (46.8%) of these isolates, non-susceptibility to TOL was explained by the production of at least one carbapenemase. WGS revealed that some isolates carried ESBLs, mutated blaPDC and ampD, associated with decreased susceptibility to TOL. Conclusion: Substitutions found in PDC and carbapenemase production were the most common presumed mechanisms of resistance to TOL detected in this study. This study shows that epidemiological surveillance is warranted to monitor the emergence of novel mechanisms of resistance to TOL that might compromise its clinical utility.Fil: Mojica, María F.. Case Western Reserve University; Estados UnidosFil: De La Cadena, Elsa. Universidad El Bosque;Fil: Ríos, Rafael. Universidad El Bosque;Fil: García Betancur, Juan Carlos. Universidad El Bosque;Fil: Díaz, Lorena. Universidad El Bosque;Fil: Reyes, Jinnethe. Universidad El Bosque;Fil: Hernández Gómez, Cristhian. Universidad El Bosque;Fil: Radice, Marcela Alejandra. Universidad de Buenos Aires; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Gales, Ana C.. Universidade Federal de Sao Paulo; BrasilFil: Castañeda Méndez, Paulo. Fundacion Clinica Medica Sur; MéxicoFil: Munita, José M.. Universidad del Desarrollo; ChileFil: Pallares, Christian José. Universidad El Bosque;Fil: Martínez, José R. W.. Universidad del Desarrollo; ChileFil: Villegas, María Virginia. Universidad El Bosque;Frontiers Media2022-10info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/217847Mojica, María F.; De La Cadena, Elsa; Ríos, Rafael; García Betancur, Juan Carlos; Díaz, Lorena; et al.; Molecular mechanisms leading to ceftolozane/tazobactam resistance in clinical isolates of Pseudomonas aeruginosa from five Latin American countries; Frontiers Media; Frontiers in Microbiology; 13; 10-2022; 1-81664-302XCONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.3389/fmicb.2022.1035609info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-22T11:19:01Zoai:ri.conicet.gov.ar:11336/217847instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-22 11:19:02.24CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Molecular mechanisms leading to ceftolozane/tazobactam resistance in clinical isolates of Pseudomonas aeruginosa from five Latin American countries
title Molecular mechanisms leading to ceftolozane/tazobactam resistance in clinical isolates of Pseudomonas aeruginosa from five Latin American countries
spellingShingle Molecular mechanisms leading to ceftolozane/tazobactam resistance in clinical isolates of Pseudomonas aeruginosa from five Latin American countries
Mojica, María F.
ANTIBIOTIC RESISTANCE
CEFTOLOZANE/TAZOBACTAM
LATIN AMERICA
MOLECULAR MECHANISMS
PSEUDOMONAS AERUGINOSA
title_short Molecular mechanisms leading to ceftolozane/tazobactam resistance in clinical isolates of Pseudomonas aeruginosa from five Latin American countries
title_full Molecular mechanisms leading to ceftolozane/tazobactam resistance in clinical isolates of Pseudomonas aeruginosa from five Latin American countries
title_fullStr Molecular mechanisms leading to ceftolozane/tazobactam resistance in clinical isolates of Pseudomonas aeruginosa from five Latin American countries
title_full_unstemmed Molecular mechanisms leading to ceftolozane/tazobactam resistance in clinical isolates of Pseudomonas aeruginosa from five Latin American countries
title_sort Molecular mechanisms leading to ceftolozane/tazobactam resistance in clinical isolates of Pseudomonas aeruginosa from five Latin American countries
dc.creator.none.fl_str_mv Mojica, María F.
De La Cadena, Elsa
Ríos, Rafael
García Betancur, Juan Carlos
Díaz, Lorena
Reyes, Jinnethe
Hernández Gómez, Cristhian
Radice, Marcela Alejandra
Gales, Ana C.
Castañeda Méndez, Paulo
Munita, José M.
Pallares, Christian José
Martínez, José R. W.
Villegas, María Virginia
author Mojica, María F.
author_facet Mojica, María F.
De La Cadena, Elsa
Ríos, Rafael
García Betancur, Juan Carlos
Díaz, Lorena
Reyes, Jinnethe
Hernández Gómez, Cristhian
Radice, Marcela Alejandra
Gales, Ana C.
Castañeda Méndez, Paulo
Munita, José M.
Pallares, Christian José
Martínez, José R. W.
Villegas, María Virginia
author_role author
author2 De La Cadena, Elsa
Ríos, Rafael
García Betancur, Juan Carlos
Díaz, Lorena
Reyes, Jinnethe
Hernández Gómez, Cristhian
Radice, Marcela Alejandra
Gales, Ana C.
Castañeda Méndez, Paulo
Munita, José M.
Pallares, Christian José
Martínez, José R. W.
Villegas, María Virginia
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv ANTIBIOTIC RESISTANCE
CEFTOLOZANE/TAZOBACTAM
LATIN AMERICA
MOLECULAR MECHANISMS
PSEUDOMONAS AERUGINOSA
topic ANTIBIOTIC RESISTANCE
CEFTOLOZANE/TAZOBACTAM
LATIN AMERICA
MOLECULAR MECHANISMS
PSEUDOMONAS AERUGINOSA
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.3
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Objectives: Identify molecular mechanisms responsible for the in vitro non-susceptibility to ceftolozane/tazobactam (TOL) in a group of 158 clinical isolates of Pseudomonas aeruginosa from five Latin American countries collected before the introduction of TOL into the clinical practice. Methods: Clinical isolates of P. aeruginosa (n = 504) were collected between January 2016 and October 2017 from 20 hospitals located in Argentina, Brazil, Chile, Colombia, and Mexico. Minimum inhibitory concentrations (MICs) to TOL were determined by standard broth microdilution and interpreted according to CLSI breakpoints. Initially, production of carbapenemases in TOL non-susceptible isolates was assessed by Rapidec® followed by qPCR to detect blaKPC, blaNDM-1, blaVIM, and blaIMP. Illumina® WGS was performed for isolates in which non-susceptibility to TOL was not mediated by carbapenemases. Results: A total of 158 (31.3%) isolates were non-susceptible to TOL. In 74 (46.8%) of these isolates, non-susceptibility to TOL was explained by the production of at least one carbapenemase. WGS revealed that some isolates carried ESBLs, mutated blaPDC and ampD, associated with decreased susceptibility to TOL. Conclusion: Substitutions found in PDC and carbapenemase production were the most common presumed mechanisms of resistance to TOL detected in this study. This study shows that epidemiological surveillance is warranted to monitor the emergence of novel mechanisms of resistance to TOL that might compromise its clinical utility.
Fil: Mojica, María F.. Case Western Reserve University; Estados Unidos
Fil: De La Cadena, Elsa. Universidad El Bosque;
Fil: Ríos, Rafael. Universidad El Bosque;
Fil: García Betancur, Juan Carlos. Universidad El Bosque;
Fil: Díaz, Lorena. Universidad El Bosque;
Fil: Reyes, Jinnethe. Universidad El Bosque;
Fil: Hernández Gómez, Cristhian. Universidad El Bosque;
Fil: Radice, Marcela Alejandra. Universidad de Buenos Aires; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Gales, Ana C.. Universidade Federal de Sao Paulo; Brasil
Fil: Castañeda Méndez, Paulo. Fundacion Clinica Medica Sur; México
Fil: Munita, José M.. Universidad del Desarrollo; Chile
Fil: Pallares, Christian José. Universidad El Bosque;
Fil: Martínez, José R. W.. Universidad del Desarrollo; Chile
Fil: Villegas, María Virginia. Universidad El Bosque;
description Objectives: Identify molecular mechanisms responsible for the in vitro non-susceptibility to ceftolozane/tazobactam (TOL) in a group of 158 clinical isolates of Pseudomonas aeruginosa from five Latin American countries collected before the introduction of TOL into the clinical practice. Methods: Clinical isolates of P. aeruginosa (n = 504) were collected between January 2016 and October 2017 from 20 hospitals located in Argentina, Brazil, Chile, Colombia, and Mexico. Minimum inhibitory concentrations (MICs) to TOL were determined by standard broth microdilution and interpreted according to CLSI breakpoints. Initially, production of carbapenemases in TOL non-susceptible isolates was assessed by Rapidec® followed by qPCR to detect blaKPC, blaNDM-1, blaVIM, and blaIMP. Illumina® WGS was performed for isolates in which non-susceptibility to TOL was not mediated by carbapenemases. Results: A total of 158 (31.3%) isolates were non-susceptible to TOL. In 74 (46.8%) of these isolates, non-susceptibility to TOL was explained by the production of at least one carbapenemase. WGS revealed that some isolates carried ESBLs, mutated blaPDC and ampD, associated with decreased susceptibility to TOL. Conclusion: Substitutions found in PDC and carbapenemase production were the most common presumed mechanisms of resistance to TOL detected in this study. This study shows that epidemiological surveillance is warranted to monitor the emergence of novel mechanisms of resistance to TOL that might compromise its clinical utility.
publishDate 2022
dc.date.none.fl_str_mv 2022-10
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/217847
Mojica, María F.; De La Cadena, Elsa; Ríos, Rafael; García Betancur, Juan Carlos; Díaz, Lorena; et al.; Molecular mechanisms leading to ceftolozane/tazobactam resistance in clinical isolates of Pseudomonas aeruginosa from five Latin American countries; Frontiers Media; Frontiers in Microbiology; 13; 10-2022; 1-8
1664-302X
CONICET Digital
CONICET
url http://hdl.handle.net/11336/217847
identifier_str_mv Mojica, María F.; De La Cadena, Elsa; Ríos, Rafael; García Betancur, Juan Carlos; Díaz, Lorena; et al.; Molecular mechanisms leading to ceftolozane/tazobactam resistance in clinical isolates of Pseudomonas aeruginosa from five Latin American countries; Frontiers Media; Frontiers in Microbiology; 13; 10-2022; 1-8
1664-302X
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/doi/10.3389/fmicb.2022.1035609
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Frontiers Media
publisher.none.fl_str_mv Frontiers Media
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1846781661842243584
score 12.982451

Publicaciones similares